News

The trial was designed to determine whether longer-term treatment with an aromatase inhibitor (Femara) post tamoxifen therapy, would offer any clinical benefit to postmenopausal women with early breast

Sparlon (modafinil) tablets [C-IV] is a new formulation and proprietary dosage strength of modafinil, the active ingredient in Provigil, which is approved for the treatment of adults with

This clinical program will investigate the safety and efficacy of a novel aerosolized formulation of HCQ using Aradigm’s AERx pulmonary delivery system. The phase II trial is a

The delay follows a standard 30-day review process associated with the investigational new drug (IND) application for the intravenous form of TBC3711, Encysive Pharmaceuticals’ next-generation selective endothelin receptor

Remicade, in combination with methotrexate, can now be prescribed as first-line therapy for early rheumatoid arthritis (RA). Previously patients were required to be treated first with methotrexate alone,

Spiegelmers, from the German word spiegel – meaning mirror, exhibit high specificity and affinity and are not subject to degradation by nucleases. In addition, the two companies entered

If given the go-ahead, the initial US based trial will evaluate NOV-205 as monotherapy for chronic hepatitis C patients who have failed pegylated interferon plus ribavirin therapy. NOV-205

Under the terms of the agreement, Arius will receive an upfront licensing fee and may receive milestone payments based on progress through clinical development as well as royalties

Orphan drug designation is designed to aid the development of treatments for serious or life-threatening diseases that afflict less than 200,000 US patients a year. Special incentives are